Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johannes Duell

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
International Journal of Cancer|September 25, 2024
The future of immunotherapy for diffuse large B-cell lymphomaJohannes Duell, Jason Westin
Bone Marrow Transplantation|August 22, 2019
The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCTHermann Einsele, Leo Rasche, Max S Topp, et al.
Clinical Pharmacology and Therapeutics|February 17, 2019
Bispecific Antibodies in the Treatment of Hematologic MalignanciesJohannes Duell, Philip E Lammers, Ivana Djuretic, et al.
Annals of Hematology|February 15, 2014
The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myelomaLeo Rasche, Susanne Strifler, Johannes Duell, et al.
Plos One|May 14, 2013
The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78Leo Rasche, Johannes Duell, Charlotte Morgner, et al.
BMC Rheumatology|July 9, 2025
Comparison of T cell response to vaccination in rheumatic patients treated with Janus kinase inhibitors and TNF inhibitorsSebastian Hüper, Florian Eisele, Johannes Duell, et al.
Journal of Cancer Research and Clinical Oncology|June 4, 2021
R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvementMaximilian J Steinhardt, Franziska C Krummenast, Andreas Rosenwald, et al.
Blood|August 7, 2009
Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host diseaseClaudia Stuehler, Stephan Mielke, Manik Chatterjee, et al.
Annals of Hematology|January 31, 2012
Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 casesLeo Rasche, Corinna Bernard, Max S Topp, et al.
Journal for Immunotherapy of Cancer|January 11, 2025
Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategiesAnna Fleischer, Sophia Kurth, Johannes Duell, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
International Journal of Cancer|September 25, 2024
The future of immunotherapy for diffuse large B-cell lymphomaJohannes Duell, Jason Westin
Bone Marrow Transplantation|August 22, 2019
The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCTHermann Einsele, Leo Rasche, Max S Topp, et al.
Clinical Pharmacology and Therapeutics|February 17, 2019
Bispecific Antibodies in the Treatment of Hematologic MalignanciesJohannes Duell, Philip E Lammers, Ivana Djuretic, et al.
Annals of Hematology|February 15, 2014
The lymphoma-like polychemotherapy regimen "Dexa-BEAM" in advanced and extramedullary multiple myelomaLeo Rasche, Susanne Strifler, Johannes Duell, et al.
Plos One|May 14, 2013
The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78Leo Rasche, Johannes Duell, Charlotte Morgner, et al.
BMC Rheumatology|July 9, 2025
Comparison of T cell response to vaccination in rheumatic patients treated with Janus kinase inhibitors and TNF inhibitorsSebastian Hüper, Florian Eisele, Johannes Duell, et al.
Journal of Cancer Research and Clinical Oncology|June 4, 2021
R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvementMaximilian J Steinhardt, Franziska C Krummenast, Andreas Rosenwald, et al.
Blood|August 7, 2009
Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host diseaseClaudia Stuehler, Stephan Mielke, Manik Chatterjee, et al.
Annals of Hematology|January 31, 2012
Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 casesLeo Rasche, Corinna Bernard, Max S Topp, et al.
Journal for Immunotherapy of Cancer|January 11, 2025
Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategiesAnna Fleischer, Sophia Kurth, Johannes Duell, et al.
Pageof 5